je.st
news
Home
› Crown Bioscience To Commercialize University Of York's Prostate Cancer Models For Drug Development
Crown Bioscience To Commercialize University Of York's Prostate Cancer Models For Drug Development
2016-02-17 02:07:05| drugdiscoveryonline News Articles
Crown Bioscience Inc., a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has reached an agreement with UK’s University of York to exclusively license and commercialize the university’s unique collection of patient-derived xenograft (PDX) models for prostate cancer.
Tags: development
university
models
drug
Category:Biotechnology and Pharmaceuticals